ERBB2 and breast carcinoma: Our study demonstrates that breast cancer subclassification based on HR and HER2 expression as used in standard diagnostics bears potential for the prediction of a pCR in patients with operable breast cancer receiving neoadjuvant chemotherapy with anthracycline and taxane and has a prognostic impact.